Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP NASDAQ:CUE NASDAQ:DRRX NASDAQ:LTRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.25+2.7%$0.23$0.15▼$13.00$14.95M0.0323.77 million shs3.05 million shsCUECue Biopharma$0.83+2.6%$0.74$0.45▼$1.99$62.62M1.53512,087 shs176,285 shsDRRXDURECT$1.87-0.5%$0.83$0.48▼$2.64$58.05M0.832.89 million shs139,725 shsLTRNLantern Pharma$4.99$3.70$2.55▼$6.12$53.82M1.6414,344 shs127,249 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro+2.50%+3.32%+21.18%+23.00%+24,599,900.00%CUECue Biopharma+2.59%+12.72%+6.09%+6.54%+22.19%DRRXDURECT-0.53%+1.91%+188.58%+155.81%+42.75%LTRNLantern Pharma0.00%+4.61%+47.20%+25.38%+23.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/ACUECue Biopharma3.8566 of 5 stars3.54.00.04.70.00.80.6DRRXDURECT1.3634 of 5 stars0.03.00.04.43.70.00.0LTRNLantern Pharma2.2855 of 5 stars3.52.00.00.02.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,526.02% UpsideCUECue Biopharma 3.00Buy$4.00381.35% UpsideDRRXDURECT 2.00HoldN/AN/ALTRNLantern Pharma 3.00Buy$25.00401.00% UpsideCurrent Analyst Ratings BreakdownLatest ABP, DRRX, CUE, and LTRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025DRRXDURECTNorthland CapmkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$180K83.08N/AN/A($0.29) per share-0.85CUECue Biopharma$9.29M6.74N/AN/A$0.28 per share2.97DRRXDURECT$2.03M28.59N/AN/A$0.29 per share6.45LTRNLantern PharmaN/AN/AN/AN/A$1.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-198.95%N/ACUECue Biopharma-$40.67M-$0.67N/AN/AN/A-507.87%-228.43%-114.66%8/13/2025 (Estimated)DRRXDURECT-$8.32M-$0.15N/AN/AN/A-91.54%-267.36%-64.00%8/12/2025 (Estimated)LTRNLantern Pharma-$20.78M-$1.84N/AN/AN/AN/A-83.26%-70.65%8/14/2025 (Estimated)Latest ABP, DRRX, CUE, and LTRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025LTRNLantern Pharma-$0.53N/AN/AN/AN/AN/A8/13/2025Q2 2025CUECue Biopharma-$0.13N/AN/AN/A$2.00 millionN/A8/12/2025Q2 2025DRRXDURECT-$0.13N/AN/AN/A$0.32 millionN/A5/15/2025N/AABPAbproN/A-$0.08N/A-$0.08N/AN/A5/15/2025Q1 2025LTRNLantern Pharma-$0.49-$0.42+$0.07-$0.42N/AN/A5/12/2025Q1 2025CUECue Biopharma-$0.14-$0.17-$0.03-$0.17$0.90 million$0.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.110.11CUECue BiopharmaN/A1.031.03DRRXDURECTN/A1.231.22LTRNLantern PharmaN/A4.864.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%CUECue Biopharma35.04%DRRXDURECT28.03%LTRNLantern Pharma28.62%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%CUECue Biopharma10.78%DRRXDURECT3.20%LTRNLantern Pharma7.31%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1560.79 million48.14 millionN/ACUECue Biopharma6075.35 million67.23 millionOptionableDRRXDURECT8031.04 million30.05 millionOptionableLTRNLantern Pharma2010.78 million10.00 millionOptionableABP, DRRX, CUE, and LTRN HeadlinesRecent News About These CompaniesLantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% AccuracyAugust 7 at 10:33 AM | theglobeandmail.comLantern Pharma (LTRN) Projected to Post Quarterly Earnings on ThursdayAugust 7 at 2:15 AM | americanbankingnews.comLantern Pharma (LTRN) Expected to Announce Quarterly Earnings on ThursdayAugust 7 at 2:14 AM | marketbeat.comShort Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Grows By 109.5%August 6 at 6:59 AM | marketbeat.comLantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™August 4, 2025 | businesswire.comLantern Pharma (LTRN) Gets a Buy from Lake StreetAugust 4, 2025 | theglobeandmail.comLantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in JapanJuly 31, 2025 | theglobeandmail.comLantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300July 31, 2025 | businesswire.comLantern Pharma Appoints Dr. Schalop to BoardJuly 30, 2025 | msn.comLantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision OncologyJuly 28, 2025 | theglobeandmail.comLantern Pharma Announces Appointment of Dr. Lee Schalop to Board of DirectorsJuly 28, 2025 | businesswire.comLantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVJuly 26, 2025 | miamiherald.comMLantern reports complete response in pretreated Lymphoma patient with LP-284July 24, 2025 | msn.comLantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical TrialJuly 23, 2025 | businesswire.comLantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer TherapyJuly 21, 2025 | businesswire.comIBN Initiates Coverage of Lantern Pharma Inc.July 16, 2025 | finance.yahoo.comLantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer TreatmentJuly 15, 2025 | theglobeandmail.comLantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer TreatmentJuly 15, 2025 | businesswire.comNASDAQ:LTRN Financials | Lantern Pharma Inc - Investing.comJuly 9, 2025 | investing.comLantern Pharma Enters ATM Sales Agreement with ThinkEquityJuly 3, 2025 | tipranks.comLung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two YearsJune 16, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABP, DRRX, CUE, and LTRN Company DescriptionsAbpro NASDAQ:ABP$0.25 +0.01 (+2.71%) As of 08/8/2025 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Cue Biopharma NASDAQ:CUE$0.83 +0.02 (+2.59%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.83 0.00 (-0.24%) As of 08/8/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.DURECT NASDAQ:DRRX$1.87 -0.01 (-0.53%) As of 08/8/2025 04:00 PM EasternDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Lantern Pharma NASDAQ:LTRN$4.99 0.00 (0.00%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$4.96 -0.03 (-0.60%) As of 08/8/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
